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SUMMARY
The selective inhibition of bacterial β-glucuronidases was recently shown to alleviate drug-
induced gastrointestinal toxicity in mice, including the damage caused by the widely used 
anticancer drug irinotecan. Here, we report crystal structures of representative β-glucuronidases 
from the Firmicutes Streptococcus agalactiae and Clostridium perfringens and the 
Proteobacterium Escherichia coli, and the characterization of a β-glucuronidase from the 
Bacteroidetes Bacteroides fragilis. While largely similar in structure, these enzymes exhibit 
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microbiome maintains functional diversity in orthologous enzymes. Small changes in the structure 
of designed inhibitors can induce significant conformational changes in the β-glucuronidase active 
site. Finally, we establish that β-glucuronidase inhibition does not alter the serum 
pharmacokinetics of irinotecan or its metabolites in mice. Together, the data presented advance 
our in vitro and in vivo understanding of the microbial β-glucuronidases, a promising new set of 
targets for controlling drug-induced gastrointestinal toxicity.
Graphical Abstract
INTRODUCTION
It is increasingly clear that the bacteria that live on and within the human body are involved 
in a range of physiological processes. Changes to the microbiota have been found to 
accompany several disease states, including diabetes, atherosclerosis, obesity, malnutrition, 
cancer, gastrointestinal (GI) inflammatory disorders, and neurological diseases (Cho et al., 
2012; Hsiao et al., 2013; Methé et al., 2012; The Human Microbiome Project Consortium, 
2012; Morgan et al., 2012; Nicholson et al., 2012; Plottel and Blaser, 2011; Smith et al., 
2013; Turnbaugh et al., 2006; Wang et al., 2011). Ongoing chemical interactions between 
mammalian tissues and their colonizing microbiota appear to play important roles in the 
symbiosis that sustains both domains of life (Mani et al., 2014; Redinbo, 2014). A key 
player in this interplay is glucuronic acid. This small sugar is conjugated, typically in the 
liver, to drugs and endobiotics marked for excretion, commonly via the bile duct to the GI 
tract (Holmes et al., 2011). In their glucuronidated states, most chemicals are inactive. The 
GI microbiota, however, contain β-glucuronidase enzymes that scavenge this sugar as a 
source of carbon. Removal of the glucuronide moiety produces aglycones that are often still 
eliminated, although they can be reabsorbed into the plasma and return to the liver as part of 
normal enterohepatic recycling. Importantly, reactivated aglycones can also be highly toxic 
to the GI tissues, and, as outlined below, there is evidence that such compounds can lead to 
serious side effects in human patients (Wallace and Redinbo, 2013).
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Irinotecan (CPT-11) is a potent anticancer drug used to treat solid tumors and other 
malignancies (Cunningham et al., 1998; Douillard et al., 2000; Hurwitz et al., 2004). It is an 
essential component of FOLFIRI (where IRI indicates irinotecan), which is widely used for 
late-stage colorectal cancer (Kelly and Goldberg, 2005), and FOLFIRINOX, which was 
recently recommended as the first-line regimen for pancreatic cancer (Conroy et al., 2011). 
Irinotecan causes severe diarrhea in a significant fraction of patients, commonly leading to 
dose reductions or treatment termination (Chabot, 1996; Ma and McLeod, 2003; Mathijssen 
et al., 2001). The irinotecan prodrug is activated to the human topoisomerase I poison SN-38 
in patients; this active metabolite is further processed by UDP-glucuronosyltransferases to 
become the inactivated glucuronide conjugate SN-38-G, which is sent to the GI tract for 
elimination (Chabot, 1996; Ma and McLeod, 2003) (Figure S1). In the GI tract, bacterial β-
glucuronidase enzymes remove the glucuronic acid and reactivate the topoisomerase I 
poison SN-38, which causes GI damage and the diarrhea that is dose-limiting for irinotecan 
(Dranitsaris et al., 2005; Gupta et al., 1994; Rothenberg et al., 2001; Stein et al., 2010) 
(Figure S1). According to the Food and Drug Administration package insert for irinotecan, 
up to 88% of patients experience diarrhea and 31% show grade 3–4 diarrhea, which requires 
significant medical intervention. Thus, the alleviation of the chemotherapy-induced diarrhea 
caused by irinotecan is an unmet medical need.
A low-potency β-glucuronidase inhibitor showed promise in 2004 in reducing the GI 
toxicity associated with irinotecan in rats (Fittkau et al., 2004). We reported more potent 
(<μM) and novel inhibitors of bacterial β-glucuronidases in 2010, and showed that they 
significantly reduced the GI damage caused by irinotecan in mice (Wallace et al., 2010). We 
showed that these inhibitors were non-toxic to both bacterial and mammalian cells, and 
demonstrated using crystal structures and other data that the inhibitors were selective for the 
bacterial β-glucuronidases by more than 1,000-fold over the human enzyme ortholog 
(Roberts et al., 2013; Wallace et al., 2010). We pinpointed the basis of the selectivity to a 
loop present in bacterial β-glucuronidases that is missing from the human enzyme ortholog; 
the inhibitors bind to this loop, making them ineffective against mammalian β-
glucuronidases (Wallace et al., 2010).
We have since demonstrated that the same approach can be applied to the non-steroidal anti-
inflammatory drugs (NSAIDs), some of the world's most widely used therapeutics (Brune 
and Hinz, 2004). NSAIDs cause serious lower GI ulcers that have been less appreciated than 
the gastric side effects more commonly associated with these compounds (Laine et al., 2003; 
Lanas, 2010). Seventy percent of long-term NSAID users have chronic lower GI 
inflammation, increased permeability, and malabsorption, 40% have ulcers, and 30% suffer 
from GI bleeding and anemia (Lanas and Sopena, 2009). Like SN-38, NSAIDs are 
inactivated by glucuronidation and reactivated in the GI tract back to the parent drugs, which 
can then cause significant enteropathy largely in the small intestine via mechanisms that are 
not completely understood (Boelsterli et al., 2012). In mouse models of GI toxicity caused 
by the NSAIDs diclofenac, ketoprofen, or indomethacin, we showed that oral dosing of 
bacterial β-glucuronidase inhibitors significantly reduced the numbers of small-intestinal 
ulcers observed (LoGuidice et al., 2012; Mani et al., 2014; Saitta et al., 2014). We also 
demonstrated that inhibition of bacterial β-glucuronidases did not alter serum levels of 
diclofenac in mice (LoGuidice et al., 2012). Thus, modulating the activity of enzymes 
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encoded by the symbiotic bacteria in the mammalian GI tract can improve tolerance to two 
classes of drugs, irinotecan and NSAIDs.
To date, these investigations have focused on the β-glucuronidase from Escherichia coli 
(Roberts et al., 2013; Wallace et al., 2010). While the Proteobacteria, including E. coli, are 
present in the mammalian GI tract, other phyla are more significantly predominant, 
particularly the Firmicutes and the Bacteroidetes (The Human Microbiome Project 
Consortium, 2012). Thus, to expand our understanding of the structure, function, and in 
vitro inhibition of bacterial β-glucuronidases, we cloned, overexpressed, purified, 
characterized, and determined the crystal structures of representative β-glucuronidases from 
the Firmicutes species Streptococcus agalactiae and Clostridium perfringens, each of which 
is present in the human GI tract. We also characterized a β-glucuronidase from Bacteroides 
fragilis, a GI microbe representative of the Bacteroidetes phylum. We demonstrate that a 
small chemical change to an inhibitor affects its efficacy, pharmacokinetics, and binding to a 
bacterial β-glucuronidase. Finally, we show that the inhibition of GI bacterial β-
glucuronidases in mice does not alter the serum levels of irinotecan or its key metabolites 
SN-38 and SN-38-G. Together, these data extend our understanding of the microbial β-
glucuronidases, which might serve as targets to reduce the toxicity and improve the efficacy 
of irinotecan and NSAIDs.
RESULTS
Crystal Structures of Firmicutes β-Glucuronidases
To advance our understanding of the structure and function of bacterial β-glucuronidase, the 
β-glucuronidases from two Firmicutes species associated with the mammalian GI 
microbiota, C. perfringens (CpGUS) and S. agalactiae (SaGUS), were cloned, 
overexpressed, and purified, and the structures of each were determined to 2.3 Å resolution 
(Figure 1A and Table S1). The structure of the β-glucuronidase from the Proteobacterial 
species E. coli (EcGUS), also present in the mammalian GI tract, was also determined in 
complex with a novel inhibitor, R1, to 2.4 Å resolution (Figure 1A and Table S1). The 
structures of the two Firmicutes enzymes are the first from this phylum. The CpGUS 
structure (PDB: 4JKM) shares 0.77 Å root-mean-square deviation (rmsd) over 453 
equivalent Cα positions with the structure of apo EcGUS (PDB: 3K46) and 48% sequence 
identity (Wallace et al., 2010). The P21212 (PDB: 4JKL) and I222 (PDB: 4JKK) SaGUS 
structures share 0.91 and 0.93 Å rmsd, respectively, over 432 and 431 equivalent Cα 
positions with the structure of E. coli β-glucuronidase. SaGUS and EcGUS share 42% 
sequence identity. The two Firmicutes enzymes, CpGUS and SaGUS, share 0.55 Å (P21212) 
and 0.56 Å (I222) rmsd over 440 and 436 equivalent Cα positions and 53% sequence 
identity. The two SaGUS structures share 0.22 Å rmsd over 527 equivalent Cα positions. 
The three microbial enzymes, CpGUS, SaGUS (P21212), and EcGUS, share 0.63, 0.85, and 
0.72 Å rmsd, respectively, with the structure of human β-glucuronidase (HsGUS, PDB: 
3HN3) (Jain et al., 1996) (Hassan et al., 2013) over 457, 424, and 441 equivalent Cα 
positions, and 46%, 38%, and 48% sequence identities, respectively. Thus, the Firmicutes 
enzymes reported here exhibit overall structures similar to the EcGUS and HsGUS 
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structures reported previously, and all are members of the glycosyl hydrolase 2 (GH2) 
family of enzymes.
β-Glucuronidase N-K Fingerprint
Using these β-glucuronidase crystal structures as a guide, we next sought to define 
functionally relevant sequence motifs. β-Glucuronidases align ether-linked glucuronides for 
hydrolysis using hydrophobic, hydrogen bonding, and electrostatic interactions with the 
glucuronic acid sugar moiety (Figure 1B). The asparagine and lysine residues that contact 
the carboxylic acid group unique to glucuronic acid relative to galactose are particularly 
critical (Figure 1B). In an alignment of β-glucuronidase sequences obtained from the NCBI, 
the asparagine and lysine (N-K) residues that contact the carboxylic acid are completely 
conserved, including in the three structures reported here (CpGUS, SaGUS, and EcGUS), as 
well as in the HsGUS enzyme (Figure 1C). This motif is present in more distantly related β-
glucuronidases from Archaeal and Thermotoga sources, as well as Bacteroides species and a 
gene obtained from uncultured sample whose gene product, H11G11, was demonstrated to 
have β-glucuronidase activity (Gloux et al., 2011) (Figure 1C). In addition to N-K, a tyrosine 
residue (Y468 or Y464 in Figure 1B) located ~4 Å from the glucuronic acid binding site 
appears to ensure by steric occlusion that only β-linked substrates are processed by the two 
catalytic glutamic acid residues of β-glucuronidases; an α linkage would clash with the 
aromatic ring at this position (Figure 1B). We examined the N-K motif region in the 
structures of GH2 family enzymes from B. fragilis (RCSB: 3CMG) and Bacteroides 
thetaiotaomicron (RCSB: 3DEC) that were deposited in the Research Collaboratory for 
Structural Bioinformatics in 2012. As shown in Figures 1C and 1D, 3CMG maintains the N-
K motif associated β-glucuronidases, while the 3DEC glycosyl hydrolase lacks the N-K 
motif and instead contains Cys and Asn residues in these locations (Figures 1C and 1D). 
Thus, 3CMG would be expected to be a β-glucuronidase, and 3DEC, because it lacks the N-
K motif, would be expected to act on distinct substrates, perhaps as a β-galactosidase. As 
shown below, 3CMG is a β-glucuronidase. Thus, the N-K sequence motif can be employed 
as a fingerprint to identify β-glucuronidases from the large GH2 family of proteins.
Bacterial and M Loops of Microbial β-Glucuronidases
The bacterial β-glucuronidases presented here contain two additional motifs unique relative 
to the human β-glucuronidase structure. First, many contain a ‘‘bacterial loop’’ that folds 
over the active sites of microbial enzymes, which processes small substrates (Wallace et al., 
2010; Figure 2A). By contrast, human β-glucuronidase, which processes larger 
glucosaminoglycan-glucuronide substrates, lacks this loop. In the CpGUS and SaGUS 
structures presented here, this loop is 14 and 13 residues in length, respectively, is visualized 
in its entirety in CpGUS, and is partially ordered in SaGUS and in the EcGUS-R1 complex 
(where it is 17 residues in length; Figures 2A and S2). The EcGUS-Inh2 structure reported 
previously contained a fully ordered loop, and a comparison of this loop and the ordered 
loop from CpGUS presented here demonstrates that this region is structurally flexible 
(Figures 2A and S2). Bacterial loops are also divergent in sequence, sharing only 11%–36% 
identity between the EcGUS, CpGUS, and SaGUS. In HsGUS, this region is replaced by a 
single residue, P415 (Figure 2A).
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Sequence analysis of bacterial loops in a set of microbial β-glucuronidase enzymes from the 
NCBI database reveals that some of the enzymes contain the loop and some do not (Figure 
2B). Phyla that encode a β-glucuronidase with an intact bacterial loop include Firmicutes, 
Proteobacteria, and Actinobacteria, as well as representatives from the fungi such as 
Aspergillus niger (Figure 2B). Phyla with β-glucuronidases lacking the bacterial loop 
include the Bacteroidetes, Dictyoglomi, and Acidobacteria. The β-glucuronidase from B. 
fragilis, 3CMG, lacks the bacterial loop. Representative β-glucuronidases in Archaea, such 
as Ignisphaera aggregans, and in Thermatogae, such as Thermotoga naphthophila (Figure 
2B), also lack the bacterial loop. All sequences in this alignment contain the conserved 
catalytic β-glucuronidase residues outlined in Figure 1B, as well as the N-K motif (see 
Figure 1C), and are therefore considered to be representative of the range of β-
glucuronidases present in sequenced microbiota.
Second, a minor structural feature unique to the microbial β-glucuronidases is the presence 
of a dipeptide within the active site composed of Leu-Met in Cp and SaGUS, and Met-Phe 
in EcGUS (Figure 2A). This motif is missing from HsGUS but is present in most, but not 
all, L-GUS and NL-GUS enzymes from NCBI sequences (Figure 2C). Due to the prevalence 
of Met residues in this short region, we refer to it as the M loop. In the Cp, Sa, and EcGUS 
structures, this region is located ~7.5 Å from catalytic residue E413 and contacts bound 
inhibitors, suggesting that it may play a role in substrate binding and catalytic function.
Based on these sequence and structural considerations, we propose that microbial β-
glucuronidases can be divided into two major groups: the L-GUS enzymes (loop-β-
glucuronidases), resembling the initially characterized bacterial enzymes and containing a 
bacterial loop, and the NL-GUS (no-loop) enzymes, which, as shown here, maintain all 
major features of β-glucuronidases but lack the bacterial loop. As shown in more detail 
below, these groupings provide a useful tool in understanding the β-glucuronidases of 
known sequence.
Microbial β-Glucuronidases Are Distinct in Catalytic Activity and Inhibition
We compared the kcat, KM, and catalytic efficiencies (kcat/KM) of the microbial β-
glucuronidases examined here using the standard p-nitrophenyl glucuronide β-glucuronidase 
assay substrate. The B. fragilis β-glucuronidase 3CMG, a representative GUS from the 
Bacteroidetes phylum, was overexpressed in E. coli and purified for kinetic characterization. 
Marked differences in all three parameters were observed (Table 1), with EcGUS exhibiting 
the best activity (kcat = 120 s–1, KM = 0.13 mM, and kcat/KM = 920 s–1 mM–1), SaGUS 
showing moderate activity (kcat = 80 s–1, KM = 0.36 mM, and kcat/KM = 224 s–1 mM–1), and 
CpGUS demonstrating the slowest kcat (2.6 s–1), the weakest KM (1.1 mM), and the least 
catalytic efficiency kcat/KM (2.4 s–1 mM–1). The B. fragilis β-glucuronidase 3CMG (BfGUS) 
exhibited a poor KM of only 1.9 mM, but a kcat (18 s–1) roughly three times higher than 
CpGUS, and thus showed a catalytic efficiency nearly five times higher than CpGUS. These 
data establish for the first time that BfGUS is a β-glucuronidase, and that the four enzymes 
from three representative GI bacterial phyla exhibit a range of catalytic efficiencies with this 
standard β-glucuronidase assay substrate.
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We also examined the ability of the Proteobacteria and Firmicutes enzymes to be inhibited 
by Inhibitors 1–8 previously identified by a 10,000-compound high-throughput screen using 
EcGUS (Roberts et al., 2013; Wallace et al., 2010; Figure S3). These compounds all inhibit 
EcGUS, with all Ki values below 2 μM (Table S2). Two novel compounds, R1 and R3, 
which are designed analogs of Inhibitor 1 and are shown in Figure 3A, were also 
synthesized and exhibited Ki values of 1.9 and 0.61 μM, respectively, toward EcGUS, and 
EC50 values of 4.5 and 3.1 μM, respectively, in cultured E. coli cells (Tables S2 and S3). In 
previous studies, Inhibitor 1 demonstrated an EC50 of 17 nM for cultured E. coli.
Interestingly, all ten compounds exhibit markedly differential effects toward the two novel 
microbial β-glucuronidases, CpGUS and SaGUS, presented here (Table S2). For example, 
Inhibitors R1, R3, 7, and 8 show no inhibition of the Cp and Sa β-glucuronidases, but are 
0.61–2 μM inhibitors of the E. coli enzyme. Similarly, Inhibitors 2, 3, and 6 are 0.2–0.7 μM 
inhibitors of EcGUS, but are up to 16-fold weaker (e.g., 11 μM for Inhibitor 3 toward Sa 
versus 0.68 μM for Ec) toward the Firmicute enzymes from SaGUS and CpGUS. Thus, 
distinct chemotypes can exert ortholog-specific effects on the activities of purified microbial 
β-glucuronidases.
We next examined whether a no-loop (NL) β-glucuronidase from the Bacteroidetes phylum 
can be inhibited by the compounds we have in hand. We found that BfGUS is not subject to 
inhibition by Inhibitors 1–8 at up to 100-μM inhibitor concentrations (Table S2). This result 
is reminiscent of the data collected previously on the mammalian GUS from bovine, which 
was also not subject to inhibition by Inhibitors 1–8 (Roberts et al., 2013; Wallace et al., 
2010). Both bovine GUS and BfGUS are NL-GUS enzymes, in contrast to the Firmicutes 
and Proteobacteria enzymes, which are L-GUS enzymes with bacterial loops. 
Superimposing the structure of EcGUS in complex with Inhibitor 2 with BfGUS from crystal 
structure 3CMG reveals that the residues 384–393 of BfGUS would clash with the inhibitor 
binding site (Figure 2D). Furthermore, while both enzymes are shown here to form tetramers 
by multi-angle light scattering in solution, by structural analysis the tetramers they form are 
distinct (Figure S4). Indeed, BfGUS fails to maintain the dimer contacts shown previously 
for EcGUS to be involved in inhibitor binding (Wallace et al., 2010) (Figure 2D). Taken 
together, these observations provide molecular explanations for the lack of inhibition of 
BfGUS by Inhibitors 1–8. Thus, we conclude the NL-GUS enzymes will not be subject to 
inhibition by the reagents that potently inhibit the L-GUS enzymes.
Reducing Serum Exposure of Inhibitors
We next hypothesized that inhibitors intended to target enzymes in the GI lumen would be 
improved by limiting their serum exposure. We have reported previously that Inhibitor 1 
exhibits 21% oral bioavailability (F) in mice, but which increases to 99% when the animals 
are given the pan-cytochrome P450 inhibitor ABT (LoGuidice et al., 2012). This suggests 
that Inhibitor 1 is absorbed from the GI tract and is subject to metabolism by P450 enzymes. 
Thus, we sought to reduce the serum exposure of Inhibitor 1 by creating two novel analogs, 
R1 and R3 (Figures 3A, S5, and S6). The O-ethyl group from Inhibitor 1, expected from 
crystal structural analysis to accommodate derivatization, was replaced with a hydroxyl (R1) 
or morpholine (R3) group, each hypothesized to reduce GI absorption. As noted above, 
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inhibitors R1 and R3 are 0.6–2 μM inhibitors of EcGUS, but do not inhibit SaGUS and 
CpGUS at up to 100 μM. We performed preliminary pharmacokinetic (PK) studies on mice 
treated orally with Inhibitor 1 and Inhibitors R1 and R3 to determine plasma levels of these 
compounds over 24 hr, with or without the cytochrome P450 inhibitor ABT. We found that 
the R1 compound exhibited significantly reduced oral bioavailability (%F) alone or with 
ABT relative to Inhibitor 1 or R3 (Table 2). Inhibitor R1 also showed poor plasma exposure, 
as measured by maximum concentration and area under the curve, relative to Inhibitors 1 
and R3. Thus, R1 is either metabolized quickly or remains in the GI tract when given orally 
to mice. The ability of Inhibitor R1 to alleviate CPT-11-induced GI damage is examined 
below.
E. coli β-Glucuronidase-Inhibitor R1 Complex Crystal Structure
We determined the 2.4-Å resolution crystal structure of EcGUS in complex with Inhibitor 
R1. This complex revealed a surprising level of structural variability in the active-site and 
bacterial-loop regions of this microbial β-glucuronidase enzyme. Inhibitor R1 was found to 
bind in a unique manner to EcGUS when compared with its close chemical homolog, 
Inhibitor 2 (Wallace et al., 2010). Inhibitor R1 forms a hydrogen bond between catalytic 
residue E413 and this compound's phenyl ring hydroxyl (Figure 3B). In contrast, Inhibitor 2 
forms a hydrogen bond between its ethoxy group and E413 (Figure 3C), similar to that 
observed in the EcGUS-Inhibitor 3 complex (Wallace et al., 2010). Inhibitors 2 and R1 are 
rotated ~120° about the horizontal axis with respect to one another in the EcGUS active site, 
as shown in Figures 3B and 3C. We observed a significant conformational change 
associated with Inhibitor R1 binding to EcGUS. N566 and K568 of the N-K loop, and 
tyrosines 468, 469, and 472 all shift in position from 2.8 to 15Å relative to the Inhibitor 2 
bound structure (Figure 3D).
These observations define a mobile Y loop within the active site of microbial β-
glucuronidases (Figure 4A). As shown in Figures 3D and 4B, Y468, Y469, and Y472 in the 
EcGUS-R1 complex shift in position by 5.5, 9.8, and 15Å, respectively, relative to their 
locations in the Inhibitor 2-EcGUS complex. These three tyrosines are conserved in the 
sequences of the CpGUS and SaGUS enzymes examined here (Figure 4A), and can be 
labeled as YI (Y468, Y468, and Y464 in Ec, Cp, and Sa, respectively), YII (Y469, Y469, 
and Y465), and YIII (Y472, Y472, and Y468). The Y loop is capable of adopting two 
different positions in the crystal structures of microbial β-glucuronidases resolved to date, as 
noted previously (Wallace et al., 2010) and extended here. The Y-loop residues in the 
EcGUS-R1 complex are positioned nearly identically to that observed in the apo structure of 
EcGUS reported previously, and can be considered to be “inactive” because the position of 
YI sterically blocks the Lys in the N-K loop from forming a salt bridge with the carboxylate 
unique to glucuronic acid (Figure 4C). The Y-loop residues in the EcGUS-Inhibitor 2 and 3 
structures (Wallace et al., 2010), by contrast, are aligned well with those in the CpGUS and 
SaGUS structures reported here, and the Lys of the N-K loop is positioned to contact a 
bound glucuronic acid sugar (Figure 4D; see also Figure 1B). Taken together, these data 
highlight the structural plasticity present in the active sites of GUS enzymes, particularly in 
the bacterial-loop and Y-loop regions, and indicate that these shifts can affect the position of 
other regions of the enzyme, such as the N-K loop.
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Irinotecan Toxicity and Pharmacokinetics in Mice
Finally, we sought to determine how inhibition of microbial β-glucuronidase activity would 
affect irinotecan pharmacokinetics and GI damage in mice. First, we examined Inhibitor R1 
for its ability to alleviate irinotecan (CPT-11)-induced diarrhea in mice. Without inhibitor, 
mice (n = 9 per group) that receive 50 mg/kg CPT-11 intraperitoneally (i.p.) develop bloody 
diarrhea after 8–10 days, with ~25% of treated mice showing this acute side effect at day 8, 
~60% at day 9, and 100% at day 10 (Figure 5A). Inhibitors 1 and R1 were provided to the 
same number of mice twice daily by oral gavage at 10 μg per dose, for a total of 20 μg per 
day. As a positive control, the previously described Inhibitor 1 was found to reduce the 
number of mice with this side effect to 20% at day 9 and 40% at day 10. Inhibitor R1, which 
demonstrates ~10-fold reduced in vitro inhibition of EcGUS and no inhibition of the 
Firmicutes enzymes (Table S2), showed reduced alleviation of CPT-11-induced diarrhea, to 
20% of mice at day 8, 40% at day 9, and 60% at day 10 (Figure 5A). Thus, while Inhibitor 
R1 showed a potentially beneficial lack of serum exposure in mice (Table 2), it is deficient 
relative to Inhibitor 1 in its alleviation of CPT-11-induced injury.
Second, we examined the potential impact of Inhibitor 1 on the serum levels of CPT-11 and 
its key metabolites SN-38 and SN-38-G in mice. To date, it has remained unclear whether 
the reabsorption of the SN-38 created by GI microbial β-glucuronidases plays a role in 
circulating levels of this active metabolite of CPT-11. Using the same dosing scheme as 
above, plasma levels of CPT-11, SN-38, and SN-38-G were determined using mass 
spectrometry. As shown in Figures 5B and Table S4, the presence of Inhibitor 1 appears not 
to alter significantly the levels of CPT-11, SN-38, and SN-38-G. These data support the 
conclusion that inhibiting the reactivation of SN-38 from SN-38-G in the GI tract would not 
reduce serum in the SN-38 capable of reaching tumors via the serum.
DISCUSSION
Firmicutes and Bacteroidetes are the predominant microbial phyla in the mammalian GI 
tract (The Human Microbiome Project Consortium, 2012); here, we examine representative 
β-glucuronidases from each to advance our understanding of the structure and function of 
these enzymes, which are involved in drug-induced GI toxicity and its alleviation 
(LoGuidice et al., 2012; Mani et al., 2014; Roberts et al., 2013; Saitta et al., 2014; Wallace 
et al., 2010). We find that purified β-glucuronidases from the Firmicutes, Proteobacteria, and 
Bacteroidetes phyla exhibit 10-, 50-, and 100-fold differences with respect to one another in 
substrate binding, reaction rate, and catalytic efficiency, respectively (Table 1). Furthermore, 
we find that some are amenable to inhibition while others are not inhibited by a range of 
chemotypes (Table S2). These observations support the conclusion that the GI microbiome 
maintains an array of enzyme orthologs capable of scavenging glucuronic acid from a range 
of chemically distinct substrates. Diverse endobiotic, food, and xenobiotic glucuronides are 
expected to be regularly delivered to the GI tract, and thus the microbial species therein are 
poised to utilize these diverse sources of carbon. It will be of interest to determine in future 
studies whether specific symbiotic bacteria are responsible for reactivating specific drug- or 
endobiotic glucuronides. For example, a particular set of bacteria may be most efficient at 
reactivating SN-38G while another efficiently processes NSAID glucuronides. Such 
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knowledge may enable the development of more tailored inhibitors for specific drug-
induced GI enteropathies.
At the structure-function level, we find that β-glucuronidases exhibit conformational 
flexibility within their active sites, and can adopt active and inactive states (Figures 3 and 4). 
We also demonstrate that β-glucuronidases contain Asn and Lys residues (an N-K motif) in 
their active site that coordinates the carboxylate group unique to glucuronic acid relative to 
galactose (Figure 1). This observation was anticipated by the work of Matsumura and 
Ellington (2001), who evolved glucuronidase activity from galactosidase enzymes and noted 
that the N-K motif was essential. The aromatic-rich Y motif is also conserved across 
glucuronidases of known sequence; these tyrosines make contact with substrate and inhibitor 
ligands and, in the case of EcGUS, are observed to adopt distinct conformations depending 
on the nature of the ligand bound. Thus, we propose that the N-K and Y motifs should join 
the catalytic glutamic acid residues as structural features considered essential for β-
glucuronidase activity. A B. fragilis glycosyl hydrolase, the structure of which was reported 
in 2008 (RCSB: 3CMG), was annotated at that time as a β-galactosidase, an understandable 
conclusion given its significant similarity to β-galactosidases from other Bacteroides species 
(e.g., 3DEC, 3BGA). However, unlike such related β-galactosidases, 3CMG contains an N-
K motif, and here we confirm in in vitro assays that it is a β-glucuronidase. This result 
highlights the potential for using the N-K motif to identify the β-glucuronidases present in 
the GI microbiome.
We conducted a phylogenetic analysis of microbial and mammalian β-glucuronidase 
sequences from a taxonomically diverse group of cultured organisms. The resulting 
phylogenetic tree of β-glucuronidases from organisms in all three kingdoms indicates the 
tremendous diversity of β-glucuronidase sequences and the broad distribution of this gene 
across the tree of life (Figure S7). This analysis further supports the conclusion that the β-
glucuronidases can be effectively divided into those that maintain a loop of their active sites 
(L-GUS) and those that do not (NL-GUS). The majority of loop-positive bacteria are 
allocated into two phyla, Firmicutes and Actinobacteria, both prominent in the human gut. 
Sequenced representatives of the Bacteroidetes, also a prominent GI phylum, are loop-
negative, as are the mammalian β-glucuronidases. While closely related organisms generally 
share similar loop phenotypes, this not a universal feature of the tree. For example, within 
the Firmicutes (Figure S7, blue branches), some loop-positive sequences cluster with loop-
negative sequences. We also find loop-positive fungal (Figure S7, orange), archaeal 
Crenarchaeota, and even Euryarchaeota β-glucuronidases (Figure S7, cyan and light blue, 
respectively), in spite of the fact that the mammalian β-glucuronidases are loop-negative. 
The presence is likely linked to the propensity for organisms to utilize smaller glucuronides 
rather than larger ones as sources of carbon that can be scavenged. However, phylogenetic 
and biochemical analysis of Ascomycete fungi suggested previously that the β-
glucuronidase gene was horizontally transferred from bacteria, potentially enabling fungi to 
make use of glucuronic acids as a carbon source in the context of a vertebrate host (Wenzl et 
al., 2005).
We find that the presence of the active-site loop confers sensitivity to inhibition. We 
demonstrate that the NL β-glucuronidase from B. fragilis (BfGUS) is inhibited neither by the 
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eight microbial β-glucuronidase inhibitors reported previously (Wallace et al., 2010; Roberts 
et al., 2013) nor by Inhibitors R1 and R3 presented here. It was previously shown that 
deleting the loop from EcGUS creates an enzyme that retains activity but is no longer 
subject to inhibition (Wallace et al., 2010). Together, these results define a crucial functional 
difference between L and NL β-glucuronidases. We predict that NL-GUS enzymes will be 
unable to utilize glucuronide conjugates such as SN-38-G as well as the L-GUS enzymes, as 
NL-GUS proteins lack the active-site loop predicted to be necessary to close over these 
molecules. By contrast, L-GUS enzymes have been shown to utilize small glucuronides such 
as SN-38-G and diclofenac-G as substrates (Wallace et al., 2010; Roberts et al., 2013). Thus, 
the ability to selectively inhibit L-GUS enzymes over their NL-GUS counterparts appears 
particularly useful in the prevention of drug-induced GI toxicity.
We hypothesized that limiting the serum exposure of inhibitors would be beneficial to their 
efficacy, as such compounds would potentially spend more time in the GI tract. The 
designed Inhibitor 1 analog R1 did show reduced serum exposure after oral dosing in mice. 
However, it was found to be less efficacious than Inhibitor 1 in alleviating diarrhea. There 
may be several explanations for this result. First, R1 shows reduced potency against EcGUS, 
and complete lack of inhibition of SaGUS or CpGUS. Thus, it is relatively weak as an 
inhibitor in vitro, which may correspond to weak efficacy in vivo. Second, the reduction of 
Inhibitor R1 levels in the plasma could be caused by its rapid metabolism and elimination 
and not by its reduced absorption from the GI tract. Examination of intestinal contents for 
intact inhibitors, and detailed inhibitor metabolism studies, will be required to understand 
the pharmacokinetics and pharmacodynamics of the microbiota-targeted compounds in vivo.
Importantly, we find that inhibition of microbial GI β-glucuronidases does not alter the 
serum levels of CPT-11 and its key metabolites in mice. Controversy has existed over the 
route by which SN-38, the active metabolite of CPT-11, reaches colon tumors. Particularly, 
it is not clear whether the reabsorption of SN-38 reactivated by the GI microbiota from the 
GI lumen plays a significant role in colon tumor exposure, and subsequent efficacy. Recent 
data using transgenic mice have suggested that, like most chemotherapies, SN-38 delivery to 
the tumors would be expected to occur through the systemic vasculature (Chen et al., 2013). 
Furthermore, SN-38 produced in the GI lumen is subject to epithelial metabolism back to 
SN-38-G and export back to the lumen (Chen et al., 2013). The data presented here support 
the conclusion that reabsorption of reactivated SN-38 from the GI tract does not play a role 
in plasma levels of this compound, CPT-11, or SN-38-G. We therefore hypothesize that 
inhibition of GI bacterial β-glucuronidases would not negatively affect tumor response to 
CPT-11. Recent data from another group validates this hypothesis and demonstrates that 
Inhibitor 1 and other β-glucuronidase inhibitors improve tumor regression in mice receiving 
CPT-11 (Kong et al., 2014). Thus, by reducing the GI side effects of CPT-11, bacterial β-
glucuronidase inhibitors might also improve outcomes in human patients receiving CPT-11 
as part of the FOLFIRI or FOLFIRINOX regimen for colon and pancreas cancers, 
respectively.
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Conjugating glucuronic acid to chemicals marked for excretion is fundamental to xenobiotic 
and endobiotic metabolism. Glucuronide conjugates are reactivated by glucuronide-
scavenging β-glucuronidases in the GI microbiota, and such reactivated compounds can 
significantly damage the GI tract. This effect has been established for the chemotherapeutic 
irinotecan and for NSAIDs. Selective, potent, and non-lethal inhibition of bacterial β-
glucuronidases was recently shown to alleviate drug-induced GI damage. Here we elucidate 
the structure and function of β-glucuronidases from the mammalian GI microbial phyla 
Firmicutes and Bacteroidetes. We show that β-glucuronidases exhibit marked differences in 
their catalytic activities and propensities for inhibition, and that small changes in inhibitor 
structure can alter β-glucuronidase active-site conformation. A phylogeny of extant β-
glucuronidases establishes two major enzyme clusters: L-GUS enzymes with active-site 
loops, and NL-GUS enzymes without loops. GI bacterial β-glucuronidase inhibition in mice 
does not alter the serum pharmacokinetics of irinotecan, its active metabolite SN-38, or its 
inactive glucuronide SN-38-G. Furthermore, reducing inhibitor serum exposure does not 
enhance alleviation of drug-induced GI toxicity, suggesting that increasing GI residence of 
inhibitors is not essential to efficacy. Finally, unlike the Proteobacteria and Firmicutes 
enzymes, the B. fragilis β-glucuronidase is not subject to inhibition by our selective 
reagents. Together, these data advance our understanding of the structure, function, and 
inhibition of the microbial β-glucuronidases, a promising set of new therapeutic drug targets 
for controlling drug-induced GI toxicity and the first targets identified in the microbiome.
EXPERIMENTAL PROCEDURES
Protein Purification, Crystallization, and Structure Determination
Genomic DNA was derived from S. agalactiae 2603V/R (ATCC #BAA-611D-5), and was 
graciously provided by Dr. Bruce McClane (University of Pittsburgh School of Medicine) 
for C. perfringens str. 13. Enzymes were cloned by PCR into pLIC-His (S. agalactiae) and 
pLIC-MBP (C. perfringens) ligation independent cloning (LIC) vectors. The pLIC-His 
vector contains an N-terminal 6x-histidine tag, and the pLIC-MBP plasmid incorporates an 
N-terminal MBP-fusion and 6x-histidine tag. Proteins were expressed in E. coli BL21-DE3 
AI competent cells (Invitrogen) and purified by column chromatography.
Similar methods were employed for BfGUS. His-SaGUS crystals were optimized for quality 
in 0.1–0.3 M potassium thiocyanate and 20%–28% polyethylene glycol (PEG) 3350 at 
16°C. Crystals of MBP-CpGUS were grown at 16°C in 0.1 M 2-(N-
morpholino)ethanesulfonic acid (pH 6.0–6.5) and 28%–36% PEG 400. The E. coli β-
glucuronidase (EcGUS)-R1 complex crystals were obtained as first described by Wallace et 
al. (2010) with modifications for co-crystallization as described by Roberts et al. (2013). 
Crystals were flash-frozen in liquid nitrogen in preparation for X-ray data collection. 
Diffraction data were collected on the 23-ID beamline at GM/CA-CAT (Advanced Photon 
Source, Argonne National Laboratory). Data were processed using standard methods and 
structures determined by molecular replacement using the EcGUS structure as a search 
model (PDB: 3K46). Structures were refined using standard methods. See Supplemental 
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Information for more details. Coordinates and structure factors can be found at PDB: 4JKM, 
4JKK, 4JKL, 5CZK.
Enzyme Assays
Assays were performed using the His-SaGUS, MBP-CpGUS, BfGUS, and His-EcGUS 
enzymes. Kinetic assays used p-nitrophenyl glucuronide as the absorbance substrate. 
Reactions were conducted in 96-well, clear-bottom assay plates (Costar) at 37°C in a 50-μl 
total volume. The reaction was performed at 37°C and product formation was measured 
using a PHERAstar Plus microplate reader (BMG Labtech). Initial velocities were 
determined for multiple substrate and enzyme concentrations, and Michaelis-Menten 
kinetics were used to calculate KM, kcat, and catalytic efficiency. Inhibition assays were 
performed using the same enzymes to assess the efficiency of Inhibitors 1–8, R1, and R3 to 
disrupt enzymatic activity from various bacterial species. Cell-based assays to calculate 
EC50 were performed as described by Roberts et al. (2013) and Wallace et al. (2010). High-
performance liquid chromatography (HPLC) assays of SN-38-G (Santa Cruz Biotechnology) 
conversion to SN-38 (Santa Cruz) were conducted as described by Wallace et al. (2010). 
Structures were refined using standard methods. See Supplemental Information for more 
details.
CPT-11 and Inhibitor Studies in Mice
Animal experiments were performed according to the Institutional Animal Care and Use 
guidelines approved by the Institutional Animal Care and Use Committee (IACUC nos. 
20070715 and 20100711) of the Albert Einstein College of Medicine, Bronx, NY.
Alleviation of CPT-11-induced toxicity studies were performed as described previously 
(Roberts et al., 2013). Inhibitor R1 and R3 pharmacokinetic analyses were performed 
identically to those described previously (LoGuidice et al., 2012). CPT-11, SN-38, and 
SN-38-G pharmacokinetic analysis was performed as follows. CPT-11 was administered at 
50 mg/kg i.p. × 1 with or without 20 μg of Inhibitor 1 per day (oral gavage of 10 mg twice 
daily for 3 days prior to CPT-11 administration and once at CPT-11 administration) in 
Balb/cJ wild-type mice. Analytes were separated using a Shimadzu LC-20 HPLC instrument 
equipped with a Waters XBridge C18 column (2.5 mm, 2.1 × 50 mm). Quantitative analysis 
was performed by a Thermo Exactive Orbitrap mass spectrometer equipped with a heated 
electrospray ionization source, operating in positive mode with enhanced resolution and 
optimized for high dynamic range. Structures were refined using standard methods. See 
Supplemental Information for more details.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Microbiome drug targets are examined from Firmicutes and Bacteroides
• Marked differences seen in catalytic activities and propensities for inhibition
• Inhibition does not alter serum pharmacokinetics of irinotecan or its metabolites
• Phylogeny defines major enzyme groups guided by structural features
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Figure 1. Firmicutes and Bacteroidetes β-Glucuronidase Crystal Structures
(A) Novel crystal structures of bacterial β-glucuronidases, two from the Firmicutes phylum, 
Clostridium perfringens (yellow; CpGUS) and Streptococcus agalactiae (magenta; SaGUS), 
and one from the Proteobacteria phylum, Escherichia coli (EcGUS) in complex with 
designed Inhibitor R1 (blue).
(B) Superposition of the active sites the β-glucuronidases from C. perfringens (yellow) and 
S. agalactiae (magenta) on that of E. coli β-glucuronidase (green) in complex with the 
glucuronic acid mimic glucaro-δ-lactam, showing the binding of the ligand's carboxylate 
moiety (left) and indicating that the proximity of the conserved tyrosine indicated 
(YI468/464) favors the alignment of a β linkage (right) for catalysis. The labels for the two 
catalytic glutamic acid residues of each enzyme are boxed.
(C) The Asn (N) and Lys (K) residues create the N-K loop conserved in β-glucuronidases 
but not in the putative β-galactosidase 3DEC from Bacteroides thetaiotaomicron (Bt3DEC, 
purple). β-Glucuronidases listed include those presented here (e.g., CpGUS, SaGUS), as 
well as those from mammalian (Homo sapiens, HsGUS), Archaeal (ArchIa), Thermatogae 
(ThermTn), and other sources. The enzymes for which a crystal structure is available are 
underlined. ArchIa, Archaea Ignisphaera aggregans, WP_013302863; TherTn, 
Thermotogae Thermotoga naphthophila, ADA67771; BactNk, Bacteroidetes Niastella 
koreensis, AEV98753; H11G11, 745-residue protein from uncultured bacterium.
(D) The glycosyl hydrolase from B. thetaiotaomicron (PDB: 3DEC; Bt3DEC; left) lacks the 
Lys and Asn residues necessary to bind a glucuronic acid sugar for catalysis; thus, this 
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enzyme appears to be a β-galactosidase. By contrast, the glycosyl hydrolase from 
Bacteroides fragilis (PDB: 3CMG; Bf3CMG; right) maintains the active-site residues 
capable of glucuronic acid binding. The labels for the two catalytic glutamic acid residues of 
each enzyme are boxed.
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Figure 2. Bacterial- and Mammalian-Type β-Glucuronidases Exhibit Distinct Bacterial and M 
Loops
(A) The three novel bacterial β-glucuronidase structures presented here (yellow, magenta, 
blue) superimposed on the structure of human β-glucuronidase (gray) reveals both the lack 
of a bacterial loop in the mammalian enzyme, as well as the lack of an M loop in the 
mammalian enzyme (inset).
(B) The bacterial loop, boxed, is maintained in the L-GUS enzymes, including those from 
several fungi (red), but is missing from the no-loop β-glucuronidases (NL-GUS) and the B. 
thetaiotaomicron (Bt3DEC) β-galactosidase. The enzymes for which a crystal structure is 
available are underlined. PROT, Proteobacteria Vibrio harveyi, WP_005434141; ACTIN, 
Actinobacteria Corynebacterium massiliense, WP_022863751; FUNGI, Eukaryota 
Aspergillus niger, CAK36851; ArchIa, Archaea Ignisphaera aggregans, WP_013302863; 
TherTn, Thermotogae Thermotoga naphthophila, ADA67771; DICTY, Dictyoglomi 
Dictyoglomus turgidum, ACK42813; BactNk, Bacteroidetes Niastella koreensis, 
AEV98753; ACIDO, Acidobacteriua Terriglobus roseus, WP_01478374; H11G11, 745-
residue protein from uncultured bacterium.
(C) A hydrophobic M loop is missing from several no-loop β-glucuronidases (NL-GUS), 
such as HsGUS and Bf3CMG, but is present in others, and is conserved in the bacterial 
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loop-containing β-glucuronidases (L-GUS). The enzymes for which a crystal structure is 
available are underlined.
(D) Active-site superposition of EcGUS-Inh2 complex (dark blue) on BfGUS (3CMG; light 
blue) showing the catalytic residues and bacterial loop of EcGUS. The 384–393 region of 
BfGUS, which is significantly shorter than the bacterial loop of EcGUS (357–371), would 
clash with the binding site of compounds such as Inhibitor 2. In addition, in the EcGUS 
tetramer, loops from different monomers (e.g., 1 and 2 shown) participate in binding 
contacts with Inhibitor 2. BfGUS does not form an analogous tetramer and cannot form a 
similar inhibitor binding site.
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Figure 3. Novel Bacterial β-Glucuronidase Inhibitors
(A) Inhibitors R1 and R3 were designed, based on Inhibitor 1 (gray), to reduce relative GI 
absorption. Inhibitor 2, for which a crystal structure bound to E. coli β-glucuronidase is 
available, is also shown (gray).
(B) Inhibitor R1 bound to the active site of E. coli β-glucuronidase, making contacts with the 
bacterial loop, as well as two active-site tyrosines, 469 and 472. The catalytic residue E413 
is also shown, as are the β-glucuronidase fingerprint residues N566 and K568.
(C) Binding of Inhibitor 2 to the active site of E. coli β-glucuronidase (Wallace et al., 2010), 
making distinct contacts, relative to Inhibitor R1, with the bacterial loop and one active-site 
tyrosine, 472.
(D) Superposition of the active sites of E. coli β-glucuronidase bound to Inhibitors R1 (blue) 
and 2 (green) but with the ligands removed. The relative shifts in five active-site residues are 
shown, including a 15-Å movement of Y469 and a shift in the positions of the β-
glucuronidase fingerprint residues N566 and K568.
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Figure 4. Bacterial β-Glucuronidases Exhibit Dynamic Y Loops
(A) The first (YI), second (YII), and third (YIII) tyrosines of the Y loop are conserved in both 
the bacterial- and mammalian-type β-glucuronidases. See the legend of Figure 2 for labels.
(B) Superposition of the active sites of C. perfringens (yellow; CpGUS), S. agalactiae 
(magenta; SaGUS), and the E. coli Inhibitor R1 complex (blue; EcGUS-R1) showing the 
dramatic shifts in position in tyrosine residues YI (Tyr 464 or 468), YII (Tyr 465 or 469), 
and YIII (Tyr 468 or 472) of the Y loop, and in the β-glucuronidase fingerprint sequence of 
the N-K loop. The view is rotated approximately 45° about the horizontal axis relative to 
Figure 3, and the two catalytic Glu residues of each enzyme are shown.
(C) The E. coli β-glucuronidase Inhibitor R1 complex (blue; EcGUS-R1) superimposes well 
on the active site of the unliganded structure of the enzyme (purple; EcGUS apo) (Wallace 
et al., 2010).
(D) In contrast to (C), the unliganded C. perfringens (yellow; CpGUS) and S. agalactiae 
(magenta; SaGUS) β-glucuronidase structures superimpose well in this region with the 
liganded E. coli b-glucuronidase Inhibitor 2 complex (green; EcGUS-Inh2) (Wallace et al., 
2010).
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Figure 5. Microbial β-Glucuronidase Inhibitors in Mice Treated with CPT-11
(A) CPT-11 (irinotecan) produced delayed diarrhea in 25%, 60%, and 100% of mice in 8, 9, 
and 10 days, respectively. Oral delivery of Inhibitor R1, a 1.9-μM inhibitor of E. coli β-
glucuronidase, reduces the number of mice that experience diarrhea at days 9 and 10 to 40% 
and 60%, respectively, but is less effective than Inhibitor 1, a 0.16-μM inhibitor, on which it 
was based. N = 9 mice per group.
(B) The circulating plasma levels of CPT-11, its active metabolite SN-38, or its inactive 
glucuronide conjugate SN-38-G are unaffected by the oral delivery of the microbial β-
glucuronidase Inhibitor 1 (Inh1).
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Table 1
Catalytic Activity of β-Glucuronidases
Enzyme kcat (s−1) KM (mM) kcat/KM (s−1 mM−1)
EcGUS 120 ± 12 0.13 ± 0.01 920
SaGUS 80 ±2 0.36 ± 0.03 224
CpGUS 2.6 ± 0.6 1.1 ± 0.2 2.4
BfGUS 18 ± 1 1.9 ± 0.3 9.5
Data are presented as the average over ±3 experiments ± SEM for Escherichia coli (EcGUS), Clostridium perfringens (CpGUS), Streptococcus 
agalactiae (SaGUS), and Bacteroides fragilis (BfGUS) β-glucuronidases. kcat, catalytic rate; KM, Michaelis constant; kcat/KM, catalytic 
efficiency.
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Table 2
Oral Bioavailability of β-Glucuronidase Inhibitors
Tmax (hr) Cmax (ng/ml) AUC (ng/ml/hr) %F
Inh-1 0.5 510 ± 200 960 21
Inh-1 + ABT 4.0 740 ± 20 4,900 99
R1 0.3 13 ± 0.4 24 4
R1 + ABT 0.3 27 ± 20 75 12
R3 0.3 82 ± 10 140 6
R3 + ABT 1.0 780 ± 200 2,800 100
Oral bioavailability (F) with and without treatment with the pan-cytochrome P450 inhibitor ABT. Tmax, maximum time; Cmax, maximum 
concentration; AUC, area under the curve.
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